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Background
We have previously shown that antagonist anti-CD28
antibodies block CD28/CD80-86 costimulation without
perturbation of the CTLA-4/CD80-86 inhibitory pathway
and favor tolerance induction by increasing Treg sup-
pression in a CTLA-4 dependent manner. Since CTLA-4
is transducing signals that block the TCR-STOP signal,
described to allow for T cell arrest and formation of
immune synapses, we hypothesized that CTLA-4 might
play a major role in the mechanism of action of anti-
CD28 antibodies by regulating T cell motility and
synapses formation.
Materials, methods and results
Here, we generated human CD4+CD25+CD127+ Teff
and CD4+CD25highCD127lowFoxp3+ Treg cell lines and
analyzed their behavior in contact with cognate APCs
by live-cell dynamic microscopy in the presence of
CD28 and CTLA-4 antagonists. CD28 blockade pre-
vented formation of stable contacts between Teff and
APCs (11.93 ± 1.175 vs 4.167 ± 1.191 min; p<0.05),
increased Teff mobility (100.5 ± 6.032 vs 204.8 ± 17.54
µm; p<0.0001) and decreased cell activation measured
by calcium flux (0.377 ± 0.028 vs 0.154 ± 0.024 calcium
peaks/min; p<0.0001). In contrast, CD28 antagonists
enhanced Treg/APC contacts (5.057 ± 0.866 vs 13.81 ±
1.104 min; p<0.0001) and increased calcium flux (0.486 ±
0.048 vs 0.677 ± 0.06 calcium peaks/min; p<0.05), result-
ing in an increase of Treg activation. The simultaneous
blockade of CTLA-4 with antibodies or of CD80/86 with
CTLA4Ig reversed some of these effects: it restored the
STOP signal and reduced motility/velocity in Teff whereas
it increased velocity in Treg and abolished Treg/APC
contacts.
Conclusion
Our data shed light on the role of CD28 and CTLA-4
that act as a rheostat to differentially control Teff and
Treg function and clarify the observations that selective
CD28-blockade but not CD80/86 blockade reinforces
Treg cell suppression in vitro.
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